北京若生智能科技有限公司
Drug Database
PH

PHN-021 (PCNH / PHN021)

✓ Approved

PhytoHealth · 小分子 · 小分子

什么是 PHN-021？

PHN-021 是一种小分子，由PhytoHealth研发。该药已获批，用于治疗相关适应症，给药途径：Unknown。

药物档案

商品名PCNH, PHN021
公司PhytoHealth
药物类别小分子
给药途径Unknown
状态Approved
来源： ClinicalTrials.gov, PhytoHealth

治疗适应症

PHN-021 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Gastrointestinal disordersAbdominal painPhase I

相关研究文献

PubMedFrontiers in neurology2026-09-10

Effects of pricking-and-cupping bloodletting therapy on pain and skin lesions in patients with herpes zoster: a systematic review and meta-analysis.

Peng Pei P, Jiang Chengting C, Wu Min M, Zhong Pengcheng P

To systematically assess the effectiveness and safety of pricking-and-cupping bloodletting therapy in relieving pain and improving skin lesion outcomes in herpes zoster (HZ) patients. All randomized controlled trials (RCTs) exploring the therapy's impact on HZ-related pain and skin lesions were identified through a comprehensive electronic search of CNKI, VIP, Wanfang, SinoMed, PubMed, EMBASE, Web of Science, and the Cochrane Library, with the search period ranging from each database's establishment until November 2025. Included studies were assessed for quality via Cochrane Risk of Bias tool, followed by meta-analysis with Stata MP 19.5. The evidence certainty for each outcome was graded via the GRADE framework. PROSPERO Registration: CRD420251267768。. A total of 31 studies involving 2,443 patients were ultimately included in the meta-analysis. The pooled analysis demonstrated that, compared with conventional Western medicine, pricking-and-cupping bloodletting therapy yielded superior outcomes across multiple endpoints. These included Visual Analogue Scale (VAS) pain scores [SMD = -1.59, 95% CI (-2.13, -1.05), p < 0.001], overall response rate [RR = 1.12, 95% CI (1.04, 1.19), p = 0.001], time to cessation of vesicles [SMD = -0.96, 95% CI (-1.34, -0.58), p < 0.001], time to crust formation [SMD = -1.29, 95% CI (-1.74, -0.84), p < 0.001], time to pain relief [SMD = -5.93, 95% CI (-6.62, -5.25), p < 0.001], and the incidence of postherpetic neuralgia (PHN) [RR = 0.14, 95% CI (0.07, 0.27), p < 0.001]. Pricking-and-cupping bloodletting therapy shows a relative benefit in shortening the time to pain relief, accelerating skin lesion healing, and reducing the incidence of postherpetic neuralgia (PHN) in patients with herpes zoster. However, given the very low certainty of evidence as assessed by the GRADE framework, clinical interpretation should be cautious. Rigorous, large-sample, multicenter randomized controlled trials are urgently needed to validate its efficacy and strengthen the reliability of clinical evidence. https://www.crd.york.ac.uk/PROSPERO/search, identifier CRD420251267768.

PMID 42718774
阅读全文 →
PubMedAnnals of thoracic surgery short reports2026-09-10

Presentation and Outcomes of Women and Men After Elective Proximal Aortic Surgery: Retrospective Institutional Analysis.

Picó Ana María AM, Divya Aabha A, Osho Asishana A AA, Hosseini Motahar M et al.

An increasing number of studies are demonstrating how outcomes in women are different from those in men after cardiac surgery. Current research lacks data on the outcomes in elective proximal aortic surgery. We retrospectively reviewed 1299 patients undergoing elective aortic surgery between 2010 and 2023; 347 (27.7%) were women. We examined preoperative and postoperative characteristics and analyzed the data with respect to morbidity and mortality in men compared with women. Demographic data of these cases showed that women had lower body mass index (27.4 kg/m2 vs 28.7 kg/m2; P = .001) and creatinine level (0.882 vs 1.03 mg/dL; P < .001), less hypertension (64.8% vs 74.2%; P = .001), and more chronic obstructive pulmonary disease (8.6% vs 5.1%; P = .028) but similar prevalence of diabetes and smoking. Despite that men had greater procedure length (336 minutes vs 313 minutes; P = .003) and cross-clamp time (134 minutes vs 120 minutes; P < .001), women spent more time in the intensive care unit (83.4 hours vs 55.9 hours; P = .009) and on the ventilator (40.7 hours vs 18.2 hours; P = .021), experienced more postoperative complications (54.8% vs 46.2%; P = .007), and had longer stays (9.73 days vs 7.97 days; P = .002). In-hospital mortality was similar. These results emphasize the need for sex-specific strategies in aortic surgery and further work on identifying the factors that differ between men and women that result in variable outcomes after elective aortic surgery.

PMID 42719105
阅读全文 →
PubMedThe lancet. Psychiatry2026-09-09

Association between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure: a retrospective study on two cohorts from Norway and the UK.

Park Yoomi Y, Lenk Hasan Çağın HÇ, Zhou Yitian Y, Lauschke Volker M VM et al.

Venlafaxine shows superior efficacy over SSRIs in treating major depression. Metabolism of venlafaxine is mediated by CYP2D6 with a secondary role of CYP2C19. The activity of both enzymes is determined by pharmacogenetic variability, which might affect therapeutic response to venlafaxine. We aimed to investigate associations between CYP2D6 and CYP2C19 genotypes and venlafaxine treatment failure. This retrospective, observational study included two independent, naturalistic cohorts of individuals treated with venlafaxine from the Center for Psychopharmacology (Oslo, Norway) and the UK Biobank. Participants were excluded if they were comedicated with strong CYP2D6 or CYP2C19 inhibitors (ie, bupropion, fluoxetine, paroxetine, fluvoxamine, or levomepromazine) or CYP inducers (ie, carbamazepine, phenobarbital, or phenytoin) at their last venlafaxine therapeutic drug monitoring measurement. Participants were stratified into genotype-predicted poor metabolisers (PMs), intermediate metabolisers (IMs), normal metabolisers (NMs), and ultra-rapid metabolisers (UMs). The primary outcome was treatment failure defined as switching away from venlafaxine to another antidepressant within 1 year after last exposure. People with lived experience did not contribute to the design and writing of this study. Between Jan 1, 2005, and Dec 15, 2025, 5443 participants genotyped for CYP2D6 and CYP2C19 (3315 [60·9%] women, 2128 [39·1%] men; mean age 48·9 years [SD 18·6]) were identified from the Center for Psychopharmacology. 3624 participants (2401 [66·3%] women, 1223 [33·7%] men; mean age 56·5 years [SD 9·8]) with prescription data were identified from the UK Biobank between 2006 and 2010. In the Norwegian cohort, odds of switching were 2·05 times higher in CYP2D6 PMs (95% CI 1·53-2·71, p<0·0001), 1·25 times higher in IMs (1·05-1·50, p=0·014), and 1·78 times higher in UMs (1·06-2·83, p=0·021) compared with NMs. Increased odds of switching in CYP2D6 PMs were also shown in the UK Biobank cohort (odds ratio 1·58 [95% CI 1·14-2·19], p=0·0060). CYP2C19 PM status amplified risk of failure in the Norwegian cohort with 6·11 times higher odds of switching in dual PMs versus NMs (95% CI 1·81-18·77, p=0·0019). CYP2D6 PM status was consistently associated with increased risk of venlafaxine treatment failure in two large, real-life cohorts, suggesting that pre-emptive genotyping could facilitate personalised venlafaxine therapy. European Research Council, Swedish Research Council, Novo Nordisk Foundation, Robert Bosch Foundation, National Research Foundation of Korea, and the South-Eastern Norway Regional Health Authority.

PMID 42716055
阅读全文 →
PubMedLancet (London, England)2026-09-09

Perioperative durvalumab plus fluorouracil, leucovorin, oxaliplatin, and docetaxel for resectable gastric and gastro-oesophageal junction adenocarcinoma (MATTERHORN): final results of overall survival and event-free survival by pathological response in a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial.

Janjigian Yelena Y YY, Al-Batran Salah-Eddin SE, Wainberg Zev A ZA, Muro Kei K et al.

Durvalumab plus perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) previously improved event-free survival and pathological complete response in resectable gastric and gastro-oesophageal junction adenocarcinoma. We aimed to examine its effect on overall survival. MATTERHORN is a global, randomised, double-blind, placebo-controlled, multicentre, phase 3 trial that took place in 147 medical centres in 20 countries (representing Asia, Europe, North America, and South America). Adults with histologically documented resectable gastric or gastro-oesophageal junction adenocarcinoma (eligible for radical surgery; stage II-IVa) not previously treated with anticancer therapy were eligible. Participants were randomly assigned (1:1) to perioperative durvalumab plus FLOT or placebo plus FLOT. Blocked randomisation (unique randomisation number via an interactive response technology system and randomisation and trial supply management system) was stratified by geographical region, clinical lymph node status, and PD-L1 expression. Participants were centrally assigned using the interactive response technology system and randomisation and trial supply management system. Participants received durvalumab 1500 mg or placebo intravenously every 4 weeks on day 1 of each cycle plus FLOT intravenously every 2 weeks on days 1 and 15 of each cycle for four cycles (two neoadjuvant and two adjuvant), followed by durvalumab 1500 mg or placebo intravenously every 4 weeks on day 1 of each cycle for ten additional cycles. Participants, investigators, and those assessing outcomes were masked. The previously reported primary outcome was event-free survival; overall survival in the intention-to-treat population was a key secondary endpoint and is the main endpoint reported here. Safety data were collected throughout treatment and the follow-up period (up to and including 90 days after the last dose of the trial drug) and were analysed in participants who received at least one dose of trial treatment; these data were reported previously and are summarised here. MATTERHORN is closed to recruitment but is ongoing and registered with ClinicalTrials.gov (NCT04592913). From Nov 17, 2020, to Sept 2, 2022, 1258 participants were enrolled and 948 were randomly assigned; 474 were randomly assigned to durvalumab and 474 to placebo. In a total of 948 participants, the median age was 62 years (IQR 54-68), 682 (72%) were male, and 266 (28%) were female. Overall survival significantly improved in the durvalumab versus placebo group (hazard ratio 0·78, 95% CI 0·63-0·96; p=0·021; significance threshold p<0·0499). Adverse events with the outcome of death possibly related to any trial treatment occurred in 6 (1%) of 475 participants in the durvalumab group and 2 (<1%) of 469 participants in the placebo group. Perioperative durvalumab plus FLOT improved overall survival versus placebo plus FLOT and is a new standard treatment option for patients with resectable gastric or gastro-oesophageal junction adenocarcinoma. AstraZeneca.

PMID 42716074
阅读全文 →
PubMedJournal of hospital medicine2026-09-08

Early clinical and laboratory indicators for differentiating infectious from autoimmune encephalitis in pediatric patients: A single-center retrospective cohort study.

Vela Sosa Ruth R, Uong Audrey A, Coronado-Muñoz Alvaro A

Pediatric encephalitis is associated with significant morbidity. Early recognition of autoimmune encephalitis (AE) is critical for timely immunotherapy and improved outcomes. To externally validate a previously published adult encephalitis prediction model in a pediatric cohort and identify predictors of pediatric AE. This retrospective single-center study included children 90 days to 21 years with encephalitis between January 2016 and September 2025. Clinical and laboratory data were extracted using electronic health record. External validation used published coefficients. Discrimination and calibration were assessed using receiver operating characteristic analysis and slope estimation. An exploratory multivariable logistic regression model was constructed. One hundred and twenty-six patients were included (92 autoimmune, 34 infectious). Patients with AE were significantly older (median age 14 vs. 5.5 years, p < .001). Infectious encephalitis was associated with higher serum white blood cell (WBC) (10.8 vs. 8.0 k/µL; p = .033) and cerebrospinal fluid (CSF) WBC (11 vs. 1 cells/µL; p < .001). The model showed acceptable discrimination (area under the receiver operating characteristic curve 0.774; 95% confidence interval [CI] 0.635-0.913) and calibration (slope 1.14; 95% CI 0.45-1.83). In our exploratory model (n = 80), CSF protein ≥30 mg/dL, was associated with lower odds of AE (odds ratio [OR] 0.24; 95% CI 0.07-0.80; p = .021), while increasing age was associated with higher odds (OR 1.13/year; 95% CI 1.01-1.26; p = .031). Predictors derived from an adult encephalitis model may retain some relevance in pediatrics despite physiologic differences. Specific pediatric predictors of AE included CSF protein <30 and increasing age, highlighting the need for pediatric-specific prediction tools. Multicenter studies are needed to validate models and refine thresholds.

PMID 42706839
阅读全文 →
PubMedPublic health nursing (Boston, Mass.)2026-09-07

Public Health Nurses' Contributions to Planetary Health Practice in Public Health Departments: A Qualitative Study.

LeClair Jessica J, Block Laura L, Ku Te-Lien TL, Bekemeier Betty B

Public health nurses (PHNs) may be well positioned to address planetary health challenges through their clinical, population health, and community-based roles, yet their contributions to planetary health practice remain understudied. This qualitative study used reflexive thematic analysis to examine PHNs' roles, contributions, and capacities related to planetary health practice in public health departments. Semi-structured interviews were conducted from October 2024 to February 2025 with 30 participants, including 13 PHNs, 11 public health leaders, and 6 community-based organization representatives across 10 U.S. states. Participants described a spectrum of PHN engagement in planetary health work, ranging from active practice to unrealized capacity. Four interrelated themes described mutually reinforcing dimensions of PHN practice relevant to planetary health: ethical and justice-oriented responsibility, trust-based relational care, bridging clinical and population health, and translating environmental data into action and advocacy. Across participant groups, PHNs were described as trusted community partners able to integrate clinical insight with systems-level public health action. These capacities were enacted to varying degrees across public health department contexts. Leadership support, workforce development, and organizational alignment may strengthen integration of these capacities into routine public health nursing practice.

PMID 42702891
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多PHN-021